What can you try to ease joint soreness?

Which home care may help first?

Reduce the movement that makes the joint flare, but keep some gentle motion so stiffness doesn't take over. A cool pack may soothe swelling after an activity. Warmth before movement may make the joint feel looser.

Exercise builds muscles that help carry the joint's work. Physical therapy can teach safer movement and build strength. Losing weight may reduce joint load when that applies. Home care can still help if you later choose a procedure.

What else can a clinician offer?

A clinician may discuss medicine for short-term soreness. Your current drugs and health history guide safer use. Some office procedures may also calm symptoms for a time. Ask how long relief could last and which side effects matter.

Blood-based procedures are one choice before an operation. QC Kinetix offers natural pain treatments and regenerative treatments, meaning medical providers prepare your blood and use it at the sore joint to try easing soreness. One choice is PRP, or platelet-rich plasma, made by spinning your blood and collecting a platelet-heavy portion. Concentrated PRP has still more platelets, though that fact alone doesn't show greater relief or risk.

When might surgery still make sense?

A severely worn joint may keep hurting after careful care. It can also cause pain at rest, poor sleep, or major limits. A surgeon can explain what an operation might change, though listening doesn't mean choosing surgery that day.

Blood procedures may be discussed as knee or hip surgery alternatives when an operation isn't needed now. Compare likely relief, risk, cost, and recovery for each choice. Ask how the clinician will judge whether the first care helped. Find out which care follows if the soreness remains.

Sources

1. A network meta-analysis restricted to LARGE randomized trials (at least 100 patients per group; 57 RCTs, 22,795 participants, 18 intra-articular interventions) found treatment effects were consistently larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. In the main analysis excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had no effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11, 11 trials) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86). The effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo effects.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.

2. A Bayesian network meta-analysis of 48 Level I-II randomized trials (9,338 knees) with a minimum 6-month follow-up ranked the four commonest intra-articular injections. HA and PRP both significantly improved pain versus placebo; HA, PRP and BMAC all significantly improved function versus placebo. SUCRA rankings were PRP 91.54, BMAC 76.46, HA 53.12, corticosteroid 15.18 and placebo 13.70 - corticosteroid ranked barely above placebo at six months and beyond.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis.. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

3. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

4. A 2026 systematic review of leukocyte-rich versus leukocyte-poor PRP for osteoarthritis concluded the current evidence is insufficient to determine whether adding leukocytes provides any clinical benefit, that results generally show no significant difference between the two, and that there is no conclusive evidence local reactions are caused by leukocytes specifically.

   Martin-Vega M, et al. — Leukocyte-rich versus leukocyte-poor platelet-rich plasma for Osteoarthritis: A systematic review.. Regenerative Therapy, 2026. DOI: 10.1016/j.reth.2026.101078.

5. A meta-analysis of 24 RCTs (1,653 participants) with plantar fasciitis found PRP produced significantly better VAS pain than corticosteroid at 3 and 6 months but not at 1 month or 12 months, and better AOFAS function scores at 3, 6 and 12 months. Plantar fascia thickness did not differ significantly at any time point.

   Zuo A, et al. — Platelet-Rich Plasma Versus Corticosteroids in the Treatment of Plantar Fasciitis: A Systematic Review and Meta-analysis.. American Journal of Physical Medicine & Rehabilitation, 2025. DOI: 10.1097/PHM.0000000000002677.

6. A multicenter prospective crossover randomized trial randomised 40 patients with discogenic chronic low back pain to a saline trigger-point control, intradiscal PRP, or intradiscal bone marrow concentrate, with crossover permitted for non-responders. Both PRP and BMC produced statistically significant improvement in pain and function with no adverse events, hospitalisations or surgery at 12 months - but ALL placebo patients reported under 50% relief and crossed over, and the trial was small and open-label.

   Navani A, et al. — The Safety and Effectiveness of Orthobiologic Injections for Discogenic Chronic Low Back Pain: A Multicenter Prospective, Crossover, Randomized Controlled Trial with 12 Months Follow-up.. Pain Physician, 2024.

7. A meta-analysis and metaregression of 14 RCTs (978 patients) of dextrose prolotherapy for knee OA found favourable effects on pain, global function and quality of life versus placebo injection and non-invasive control, and effects COMPARABLE to other invasive therapies at each follow-up duration - with the authors cautioning that heterogeneity and risk of bias across the included trials require the results to be interpreted cautiously.

   Chen YW, et al. — Effectiveness, Compliance, and Safety of Dextrose Prolotherapy for Knee Osteoarthritis: A Meta-Analysis and Metaregression of Randomized Controlled Trials.. Clinical Rehabilitation, 2022. DOI: 10.1177/02692155221086213.

8. A multicenter single-blind RCT randomised 200 patients 1:1:1 to a single injection of saline, hyaluronic acid or amniotic suspension allograft. ASA produced significant KOOS and VAS improvements maintained through 12 months with a 63.2% OMERACT-OARSI responder rate, no radiographic differences, and no concerning immunoglobulin or anti-HLA responses. Adverse events with ASA were comparable to HA, while NO treatment-emergent adverse events were reported in the saline group.

   Gomoll AH, et al. — Safety and Efficacy of an Amniotic Suspension Allograft Injection Over 12 Months in a Single-Blinded, Randomized Controlled Trial for Symptomatic Osteoarthritis of the Knee.. Arthroscopy, 2021. DOI: 10.1016/j.arthro.2021.02.044.

9. An analysis of internet-based marketing claims found widespread direct-to-consumer promotion of unapproved stem cell interventions by businesses based in the UNITED STATES - previously treated as a phenomenon of countries with lax medical regulation - and concluded that regulatory agencies must better oversee this marketplace.

   Turner L, Knoepfler P. — Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.. Cell Stem Cell, 2016. DOI: 10.1016/j.stem.2016.06.007.

10. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

    U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.